Alnylam Gets Some Welcome News
The FDA has agreed to allow Alnylam (NASDAQ: ALNY) and Sanofi (NYSE: SNY) to resume trials of their hemophilia therapy, fitusiran. Previously, these companies had to halt their fitusiran studies after a patient who had advanced into an extension study died because of a fatal blood clot. Is this news good for patients and investors?
Hemophilia A is caused by a deficiency of blood coagulation factor VIII and hemophilia B is caused by a deficiency of blood coagulation factor IX. In both cases, the low levels of clotting factor put patients at significant risk of bleeding and hemorrhages. It's estimated that there are about 150,000 patients with hemophilia A and 30,000 patients with hemophilia B, globally.
Image source: Getty Images.
Source: Fool.com
Alnylam Pharmace. Stock
The stock is an absolute favorite of our community with 52 Buy predictions and no Sell predictions.
Based on the current price of 189.95 € the target price of 426 € shows a potential of 124.27% for Alnylam Pharmace. which would more than double the current price.
